

POSTER PRESENTATION

Open Access

Screening of *cacna1a* and *ATP1A2* genes in hemiplegic migraine: clinical, genetic and functional studies

C Sintas^{1*}, O Carreño¹, R Corominas¹, SA Serra², M Vila³, N Fernández-Castillo¹, C Toma¹, R Pons⁴, M Llana⁵, MJ Sobrido⁶, D Grinberg¹, MA Valverde⁷, JM Fernández-Fernández⁷, A Macaya⁸, B Cormand¹

From The European Headache and Migraine Trust International Congress London, UK. 20-23 September 2012

Introduction

Hemiplegic migraine (HM) is a rare and severe subtype of autosomal dominant migraine, characterized by a complex aura including some degree of motor weakness. Mutations in three genes (*CACNA1A*, *ATP1A2* and *SCN1A*) have been detected in familial and in sporadic cases. This genetically and clinically heterogeneous disorder is often accompanied by permanent ataxia, epileptic seizures, mental retardation, and chronic progressive cerebellar atrophy.

Objectives

To perform an exhaustive mutational screening of the *CACNA1A* and *ATP1A2* genes in 18 HM patients.

Methods

Direct sequencing of PCR amplicons, Multiplex Ligation-dependent Probe Amplification (MLPA), Quantitative Multiplex PCR of Short Fluorescent fragments (QMPSF), heterologous expression and electrophysiology, ouabain survival assay.

Results

We identified four previously described missense *CACNA1A* mutations (p.Ser218Leu, p.Thr501Met, p.Arg583Gln and p.Thr666Met) and two missense changes in the *ATP1A2* gene, the previously described p.Ala606Thr and the novel variant p.Glu825Lys. Additionally, a quantitative analysis was performed to detect exonic duplications or deletions in the *CACNA1A* gene using MLPA and QMPSF, with negative results. Functional studies were performed for the *CACNA1A* p.

Thr501Met mutation and the *ATP1A2* p.Glu825Lys change, the first having been previously described only in association with the EA2 phenotype.

Conclusion

This genetic screening allowed the identification of more than 30% of the disease alleles. Functional studies performed with two of the identified changes suggest that they are disease-causing.

Author details

¹Departament de Genètica, Facultat de Biologia, Universitat de Barcelona, Spain. ²Department of Experimental and Health Sciences, UPF, Spain. ³Pediatric Neurology Research Group, Vall d'Hebron, Spain. ⁴First Department of Pediatrics, Agia Sofia Hospital, University of Athens, Athens, Greece. ⁵Sección de Neurología, Complejo Hospitalario Arquitecto Marcide-Novoa Santos, Ferrol, Spain. ⁶Fundación Pública Galega de Medicina Xenómica, Santiago de Compostela, Spain. ⁷Laboratory of Molecular Physiology and Channelopathies, Department of Experimental and Health Sciences, UPF, Spain. ⁸Pediatric Neurology Research Group, Vall d'Hebron Research Institute, Spain.

Published: 21 February 2013

References

1. Cuenca-Leon E, *et al*: Genetic analysis of 27 Spanish patients with hemiplegic migraine, basilar-type migraine and childhood periodic syndromes. *Cephalalgia* 2008, **28**(10):1039-47.
2. Serra SA, *et al*: The hemiplegic migraine-associated Y1245C mutation in *CACNA1A* results in a gain of channel function due to its effect on the voltage sensor and G-protein-mediated inhibition. *Pflugers Arch* 2009, **458**(3):489-502.

doi:10.1186/1129-2377-14-S1-P26

Cite this article as: Sintas *et al.*: Screening of *cacna1a* and *ATP1A2* genes in hemiplegic migraine: clinical, genetic and functional studies. *The Journal of Headache and Pain* 2013 **14**(Suppl 1):P26.

¹Departament de Genètica, Facultat de Biologia, Universitat de Barcelona, Spain

Full list of author information is available at the end of the article